# E10A for the Treatment of Squamous Cell Carcinoma of the Head and Neck

> **NCT02630264** · PHASE3 · UNKNOWN · sponsor: **Guangzhou Double Bioproducts Co., Ltd** · enrollment: 540 (estimated)

## Conditions studied

- Head and Neck Neoplasms

## Interventions

- **DRUG:** Endostatins
- **DRUG:** Paclitaxel injection
- **DRUG:** Cisplatin injection

## Key facts

- **NCT ID:** NCT02630264
- **Lead sponsor:** Guangzhou Double Bioproducts Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-06
- **Primary completion:** 2016-06
- **Final completion:** 2016-12
- **Target enrollment:** 540 (ESTIMATED)
- **Last updated:** 2015-12-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02630264

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02630264, "E10A for the Treatment of Squamous Cell Carcinoma of the Head and Neck". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT02630264. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*